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Abstract
Background: Much research worldwide is focussed on cost containment and better adherence to guidelines in
healthcare. The research focussing on professional behaviour is often performed in a well-controlled research
setting. In this study a large-scale implementation of a peer review strategy was tested on both test ordering and
prescribing behaviour in primary care in the normal quality improvement setting.
Methods: We planned a cluster-RCT in existing local quality improvement collaboratives (LQICs) in primary care.
The study ran from January 2008 to January 2011. LQICs were randomly assigned to one of two trial arms, with
each arm receiving the same intervention of audit and feedback combined with peer review. Both arms were
offered five different clinical topics and acted as blind controls for the other arm. The differences in test ordering
rates and prescribing rates between both arms were analysed in an intention-to-treat pre-post analysis and a
per-protocol analysis.
Results: Twenty-one LQIC groups, including 197 GPs working in 88 practices, entered the trial. The intention-
to-treat analysis did not show a difference in the changes in test ordering or prescribing performance between
intervention and control groups. The per-protocol analysis showed positive results for half of the clinical topics. The
increase in total tests ordered was 3% in the intervention arm and 15% in the control arm. For prescribing the increase
in prescriptions was 20% in the intervention arm and 66% in the control group. It was observed that the groups with
the highest baseline test ordering and prescription volumes showed the largest improvements.
Conclusions: Our study shows that the results from earlier work could not be confirmed by our attempt to implement
the strategy in the field. We did not see a decrease in the volumes of tests ordered or of the drugs prescribed
but were able to show a lesser increase instead. Implementing the peer review with audit and feedback proved
to be not feasible in primary care in the Netherlands.
Trial Registration: This trial was registered at the Dutch trial register under number ISRCTN40008171 on
August 7th 2007.
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Background
Spiralling healthcare costs are a major concern for pol-
icymakers worldwide. Overuse, underuse and misuse of
healthcare are estimated to be responsible for 30% of the
total spending on healthcare annually. It has been esti-
mated that 7% of the wasted healthcare spending in the
US is due to overtreatment, including test ordering and
prescribing [1]. In the years 2004–2011, the average an-
nual growth in the number of prescriptions in the
Netherlands was 5.7%; in fact, the growth of the national
income of the Netherlands has been smaller than the
growth of the healthcare budget year after year [2, 3]. If
nothing is done to reduce the growth in healthcare
spending, it is feared that Western countries will not be
able to pay the healthcare bill in the long term. There-
fore, physicians are being targeted by policymakers to
contribute on reducing waste in healthcare, and are en-
couraged to alter their habits.
An unsolved problem with changing professional be-
haviour is the lack of a clear and solid benchmark for
the desired behaviour [4, 5]. This can be overcome by
using practice variations as a proxy for quality of care. A
certain degree of practice variation is clearly warranted,
given the unique profiles of individual patients and prac-
tice populations. However, when practice variation is
caused by underuse or overuse of care, this results in
unwarranted variation and thus inappropriate care [6].
In the Netherlands, general practitioners (GPs) now
have access to over 100 evidence-based clinical practice
guidelines. These guidelines have been developed by
the Dutch College of General Practitioners (NHG) with
the aim of reducing unwarranted practice variation and
improving the quality of care provided. Although the
general adherence to these guidelines seems quite
reasonable, viz. approximately 70%, there is consider-
able practice variation in test ordering and prescribing,
indicating room for improvement in poorly performing
practices [7–12].
In local quality improvement collaboratives (LQICs),
general practitioners meet on a regular basis to discuss
current issues and gain new insights concerning test or-
dering and prescribing behaviour. Healthcare organisa-
tions and governments promote these meetings as a
means to implement guidelines. LQICs are widely imple-
mented in primary care, mainly in Europe and, to a
lesser degree, in North America. Local pharmacists are
members of these groups and are well respected for their
input and knowledge.
These LQICs are an attractive target for interventions
aimed at changing professional behaviour both effectively
and efficaciously [13–20]. In a robust trial on three clinical
topics, Verstappen et al. showed the beneficial effects of a
multifaceted strategy involving audit and feedback with
peer review in LQICs on test ordering behaviour. They
found a reduction in the volumes of tests ordered ranging
from 8 to 12% for the various clinical topics [21, 22].
Lagerlov et al. showed that individual feedback embedded
in local peer group discussions improved appropriate
treatment of asthma patients by 21% and urinary tract
infections by 108%, compared to baseline values [23].
There is also evidence suggesting that the mere provision
of information on test fees when presented at the time of
the order entry reduces the volumes of tests ordered [24].
Most of this evidence, however, stems from trials fo-
cussing on a single or limited number of clinical topics,
and involving a strong influence of the researcher on the
participants, e.g. as moderator during sessions. More-
over, in the Verstappen trial, the included groups were
selected by the researcher and can be regarded as innov-
ator groups. We wanted to build on the experiences
from the work by Verstappen et al. and undertake a
large-scale implementation of the strategy in a pragmatic
trial with much room for the LQICs to adapt the strategy
to their own needs and without any researchers being
present embedded within the existing network of LQICs.
We hypothesized that our intervention would reduce
inappropriate testing and prescribing behaviour. Our
research question was therefore: What is the effect of
audit and feedback with peer review on general practi-
tioners’ prescribing and test ordering performance?
We also report the sum scores of volumes of tests and
prescriptions in a per-protocol analysis. This analysis
was not planned in the study protocol [16], but we
decided to add it as the process evaluation of the study
revealed that the uptake of the strategy was much lower
than expected [25].
Methods
Design
We conducted a two-arm cluster-randomised trial with
the LQIC as the unit of randomisation and with central
allocation. Core elements of the intervention are audit
and comparative feedback on test ordering and prescrib-
ing volumes, dissemination of guidelines and peer review
in quality improvement collaboratives moderated by
local opinion leaders [16].
The intervention started in January 2008 and was
completed as planned at the end of December 2010. We
measured baseline performance during the six months
before the intervention, and follow-up performance dur-
ing the six months after the intervention. The design of
this intervention is described in more detail in the trial
protocol [16].
Setting and Participants
Recruitment was restricted to the south of the
Netherlands, because of our access to prescribing data of
GPs working in this area. First, the regional health officers
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or key laboratory specialists for all 24 primary care diag-
nostic facilities in the south of the Netherlands were iden-
tified and recruited by the first author. They were trained
in a three hour session in their region by the researchers.
Object of this training was to transfer knowledge on ef-
fectively discussing test ordering and prescribing behav-
iour, setting working agreements, on how to effectively
moderate meetings and how to deal with questions on the
validity of the feedback data or other aspects of the inter-
vention. Also written and digital materials where made
available to enable them to facilitate recruitment of LQIC
groups. The routines of the LQICs were deliberately left
unchanged as they represented normal quality improve-
ment routines in primary care in the Netherlands. Only
when test ordering was discussed a laboratory specialist
from the diagnostic facility moderated the group discus-
sion. The strategy was new to all participants in this trial.
Intervention
In this trial with audit and feedback with peer review in
LQICs we wanted to test the results on test ordering be-
haviour and prescribing behaviour of the strategy. Ag-
gregated comparative feedback was provided on tests
ordered or drugs prescribed in the period of six months
before each meeting in which it was discussed. Feedback
was sent to the moderator for that session (the local
pharmacist or laboratory specialist). At the start of each
meeting, each GP received feedback report on their own
performance together with an outline of the recommen-
dations from the guidelines, validated by clinical experts
(Additional file 1: Appendix 1). The feedback was ad-
justed for practice size and compared with the aggre-
gated results from their practice, their LQIC group and
neighbouring groups (Fig. 1). To mimic the normal
situation in self-directing LQIC groups, the groups in
both arms were allowed to choose three clinical topics
out of a set of five presented to them. The set of five
topics differed between the two arms (Table 1). Each
group planned two paired meetings for each topic, one
on test ordering and one on prescribing making it a total
of six meetings. Each meeting lasted between 90 and
120 min as was usual before depending on the intensity
of the discussion. Groups were encouraged by the
trained moderator (see under “setting and participants”)
to establish working agreements to improve their per-
formance, and to discuss barriers to change. The LQICs
were allowed to adapt the format of the meeting to their
own needs and routines, as long as peer review and
working agreements were included. At the end of each
meeting groups where asked to fill out a form stating
what working agreements and goals were set.
Feedback reports were generated from two main data-
bases, one on diagnostic tests and one on prescriptions,
with data originating from primary care diagnostic facil-
ities and the two dominant insurance companies in the
region. The databases contained data on the specific test
or drug, the date it was ordered or prescribed, the prac-
tice in which the physician who had ordered or pre-
scribed it worked, the date of birth of the patient, their
gender and, in the case of prescriptions, the number of
defined daily dosages (DDDs) that were prescribed. A
more detailed description of the intervention is available
in the previously published trial protocol [16].
Data collection and main outcome measures
The primary outcome measures were the volumes of
tests ordered and drugs prescribed per practice, per
1000 patients, per 6 months. Although data on a large
Number of tests ordered  July - January 
No of tests /1000 patients
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practice n=2
group n=6
region n=15
Fig. 1 Example of the graphical comparative feedback (this image doesn’t reflect actual data)
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number of diagnostic tests and prescriptions were avail-
able (Additional file 2: Appendix 2), only results on key
tests and drugs for each clinical topic are reported in
this paper. The identification of these key tests and
drugs was based on consensus within the research group
and one clinical expert on each topic before the inter-
vention started.
Sample size
We calculated that a total of 44 LQICs would be suffi-
cient to detect a standardised effect size (Cohens d) of
0.5, with a significance level alpha of 0.05, a power of
0.9, an ICC of 0.1 and a mean group size of seven GPs.
Anticipating a dropout rate of 10%, we would need to
recruit 50 LQICs. [10, 16].
Randomisation
Prior to the randomisation, the LQICs were stratified on
their level of group performance, as assessed by a ques-
tionnaire resulting in four levels of group work, from
‘poor’ to ‘good’. The level of group performance may be
a confounder for the ability to establish shared working
agreements and for the quality of prescribing behaviour
[26–29]. By stratifying on this, we ensured an equal dis-
tribution of these levels over the trial arms. An inde-
pendent research assistant produced a computer-
generated allocation list and allocated the LQICs to arm
A or arm B, while the researcher was blinded to this
process. Groups in both trial arms were exposed to the
same intervention, but on different clinical topics. Each
LQIC in one arm served as an unmatched control for
the LQICs in the other arm [30, 31]. Groups were
blinded to the clinical topics discussed in the other arm.
The researcher was blinded until all data analyses had
been completed.
Data analysis
To analyse the intention-to-treat differences between the
two arms we compared performances at the LQIC level
for all key tests and drugs during the six months prior to
the intervention with performances during the six
months after completion of the intervention period. We
analysed according to the intention-to-treat principle re-
gardless whether a group had chosen a clinical topic or
not. In addition, we performed a per-protocol before
and after analysis to test for effects in the groups that
had actually organised a meeting on a specific topic,
with all other groups acting as controls in the analysis.
The time intervals for our per-protocol analyses were
six months prior to each LQIC meeting, compared with
0–6 months after each LQIC meeting in the case of
tests, and 3–9 months after each meeting in the case of
prescribing (Fig. 2). By using this washout period we
avoided contamination with long-term prescriptions.
We used a Chi-square test or T-test to check if the
stratification of groups had led to an even distribution of
the LQIC group performance levels and the characteris-
tics of the participants over the trial arms and topics.
The group effect (intervention versus control) on pre-
scribing rate and test ordering rate after the intervention
was assessed using a linear mixed model with the LQIC
as a random effect to account for the clustering of prac-
tices within the LQIC. In addition, group (intervention
or control), baseline value of the outcome measure (be-
fore the intervention) and interaction between the base-
line and group were included as fixed factors. If the
interaction term was not statistically significant, it was
removed from the model, and only the overall group ef-
fect is presented. This method was used for both the
intention-to-treat analysis and the per-protocol analysis.
Table 1 Sets of clinical topics and the number of meetings
held for each topic
Clinical topic Study
arm
Number of
meetings
on test
ordering
Number of
meetings
on prescribing
Desired direction
of change
Tests Drugs
Anaemia A 9 9 ↓ =
Dyslipedemia A 2 2 ↓ =
Prostate
complaints
A 6 6 ↓ ↓
Rheumatic
complaints
A 10 10 ↓ =
UTI A 2 2 ↓ ↓
Chlamydia
trachomatis
B 8 8 ↑ ↑
Diabetes
mellitus II
B 5 4 ↓ =
Stomach
complaints
B 6 6 ↓ ↓
Perimenopausal
complaints
B 4 4 ↓ ↓
Thyroid
dysfunction
B 6 6 ↓ =
Total 58 57
Fig. 2 Graphical display of the periods defined for the baseline
and follow-up measurement of tests ordered and drugs prescribed in
the per protocol analysis
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If the interaction term was statistically significant, the
overall group effect (obtained from the model without
the interaction term) and the group effects for different
baseline values, at the 10th and 90th percentiles of the
baseline variable, are presented to assess the effects at
both ends of the spectrum. We expected that change
would mostly be seen in GPs in the 90th percentile, as
this is a clear indication of overuse and marks a need to
decrease test ordering or prescription volumes. Although
it is not clear what the benchmark is for volumes of tests
and prescriptions, we did not expect GPs at the other
end of the spectrum—the 10th percentile—to clearly fail
in terms of underuse of tests and prescriptions.
All data analyses were performed using IBM SPSS Statis-
tics for Windows, Version 21.0 (Armonk, NY: IBM Corp).
P-values ≤ 0.05 were considered statistically significant.
Exclusion of data before analysis
At the time when the intervention was designed, the rec-
ommendations for dyslipidemia and type 2 diabetes mel-
litus were provided in two separate guidelines. However,
at the start of the actual intervention, the guidelines on
diabetes management and dyslipidemia treatment were
merged into one new, multidisciplinary national guide-
line on cardiovascular risk management. This was dir-
ectly followed by a massive government led intervention
to transfer care for diabetics and cardiovascular risk pa-
tients from specialist care to GPs. Part of this transfer
was the institution of a pay for performance model for
these two topics together with the introduction of many
outcome indicators being tracked by newly introduced
and completely integrated software [32]. As part of this
campaign much publicity was created in both the profes-
sional and public media. This caused substantial contam-
ination of our intervention contrast, resulting in an
inability to interpret the results on these clinical topics.
Therefore, we chose to exclude the topics of dyslipidemia
and type 2 diabetes mellitus from the analyses. The results
on test ordering for the clinical topics of urinary tract in-
fections (UTI) and stomach complaints could not be cal-
culated either, due to insufficient data on test ordering
from laboratories and diagnostic facilities to report these
data (e.g., urine cultures and gastroscopies). Results on
prescription rates for Chlamydia are not shown because it
proved impossible to link the prescribed antibiotics reli-
ably to this condition. This problem did not occur for
UTI, as we confined the data to nitrofurantoin and tri-
methoprim, which are antibiotics that are only indicated
or prescribed for UTI treatment in Dutch primary care.
Results
Participants
Out of the 24 primary care diagnostic facilities (labora-
tories) we approached, 12 actually managed to recruit 21
LQICs for the trial (Fig. 3). The other facilities did not
manage to recruit due to various reasons, which is
described in detail in the process evaluation. The 21
groups consisted of 197 GPs working in 88 practices,
and 39 community pharmacists. Eight laboratory special-
ists participated in the groups when test ordering was
being discussed. The characteristics of the participating
groups and the GP members of these groups are de-
scribed in Table 2.
Results of the intention-to-treat analysis
The intention-to-treat before and after analyses on test
ordering did not show any differences between the
intervention and control groups, with wide confidence
intervals, all including 0, and all with p-values well
above 0.05 (Table 3). Interaction with the baseline
values was present for rheumatic complaints. This
showed a difference in the desired direction in number
of tests ordered for the practices within the p90 range
of test ordering only.
The intention-to-treat analysis on drug prescriptions
showed a difference in the desired direction for misopros-
tol only. Interaction with baseline values was present for
misoprostol, the triple therapy for Helicobacter pylori
eradication (PantoPac®), antithyroid preparation drugs and
clonidine (Table 4), showing changes in the desired direc-
tion for misoprostol, antithyroid preparations and cloni-
dine. This effect is not present for the prescription rates of
triple therapy at either p10 and p90.
Results of the per-protocol results
Table 5 shows the results of the per-protocol analyses
on test ordering volumes for all groups that covered
a specific topic (intervention group) compared to all
other groups (controls). We found a difference be-
tween both trial arms in the desired direction in test
ordering only for thyroid dysfunction and perimeno-
pausal complaints.
Testing for interaction with baseline measurements
showed a difference in test ordering rates in the desired
direction for those GP practices with a baseline test-
ordering rate at or above p90 for chlamydia infections,
rheumatic complaints and perimenopausal complaints.
Table 6 shows the results of the per-protocol ana-
lysis on prescribing performance. A difference in the
overall volume of all prescribed drugs between inter-
vention groups and their controls was observed for
medication prescribed for prostate complaints (, stom-
ach complaints and thyroid dysfunction. For each of
the clinical topics we also analysed each Anatomical
Therapeutic Chemical Classification System (ATC)
group in that topic separately, as changes found for
specific ATC groups could represent clinically rele-
vant changes. These results are shown in more detail
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in Table 6. Testing for interaction with baseline measure-
ments again showed a statistically significant interaction
for several topics and specific ATC groups. All showed
larger differences in prescribing rates before and after the
intervention for the practices in the p90 range than for
those in the p10 range (Table 6).
Discussion
Summary of the main findings
Our study found that the beneficial results obtained in
earlier, well-controlled studies on audit and feedback
with peer review in LQICs in primary care were not
confirmed when we introduced this intervention in
Fig. 3 Flowchart of recruitment of laboratories, laboratory specialists or regional health officers and their recruitment of LQICs with the
number of GPs in brackets
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existing primary care LQICs. The per-protocol analyses
showed that GPs from practices with the highest base-
line volumes on test-ordering and prescribing showed
the largest improvements.
Many participant and context related factors can be
identified as possible explanations for the lack of overall
effects of our intervention. Lack of confidence in and ad-
herence to the strategy emerged during the trial; The
origin and validity of the feedback was questioned by
some participants, while others felt that this intervention
was too complex and too ambitious. Although we pro-
vided complete transparency on the data sources and
instructed the moderators in this respect, we learned
from the process evaluation that the source of the feed-
back was often not clear to the participants [25]. We
found that many groups failed to set achievable and
measurable working agreements. More than half of the
meeting reports we received from groups did not con-
tain specific, achievable, realistic or measurable working
agreements. What also seemed to have occurred is the
phenomenon of choosing topics for quality improvement
for which the group already showed good performance,
the Sibley effect [33].
In a recently published article on how to provide feed-
back effectively Brehaut et al. provide 15 suggestions for
designing and delivering effective feedback. [34] The
feedback we provided meets all these suggestions but
three. First providing the feedback as soon as possible at
optimal intervals was not possible in our trial as we pro-
vided feedback on demand of the LQICs. Secondly we
did not provide the feedback in more than one way, this
could indeed have been helpful. The last suggestion we
(partially) missed is to provide short key messages with
an option to have extra detailed information on demand.
This was impossible in this trial with the use of peer re-
view as a means to discuss the feedback. Would we have
provided key messages on individual feedback we would
have impaired or at least influenced the peer review
process, an essential part of LQIC work. When we look
at the criteria for effective audit and feedback as defined
by Ivers et al. in their somewhat older Cochrane review
we conclude that we meet most criteria except including
exclusively practices with poor baseline performance and
the provision of predefined goals [35]. Including prac-
tices with poor baseline performance would have forced
us to leave the stable and safe environment of the exist-
ing LQICs. The peer review effect where poorly per-
forming GPs can learn from role models would have
been impaired and the negative effects of an organisa-
tional reform would have occurred [8, 36, 37]. The
provision of aggregated results from their own and
neighbouring groups, together with the recommenda-
tions from clinical guidelines, can be regarded as implicit
goal setting [21]. However we acknowledge that this dif-
fers to a greater extend from the definition of predefined
goals suggested by Ivers et. al. [25].
We clearly underestimated the influence of a health-
care reform that was launched shortly after the start of
this trial. As a result much specialist care was trans-
ferred to primary care, with Dutch GPs earning a higher
income but at the same time feeling threatened in their
autonomy and time management. Last but not least, the
Table 2 Characteristics of the participating GPs and groups
Arm A Arm B p
Number of groups 10 11 0.40
Number of practices 39 49 0.45
Mean group size (GPs per group) 8.1 (0.64a) 10.55 (1.70a) 0.20
Mean group level 2.70 (0.26a) 2.82 (0.33a) 0.78
No. of men (n total) 53 (81) 78 (116) 0.791
Mean age of GPs 47.9 (0.91a) 47.1 (0.77a) 0.538
aStandard deviation
Table 3 Intention-to-treat analysis of changes in test ordering rates
Intervention Control
Clinical topic n Mean before (sd) Mean after (sd) n Mean before (sd) Mean after (sd) Ba (95% CI) icc Direction p
Anaemia 39 177.8 (173.1) 208.4 (216.9) 49 208.1 (148.7) 247.3 (176.7) 15.3 (−53.7, 83.3) 0.31 ↓ 0.630
Rheumatic complaints 39 12.9 (20.1) 13.1 (23.0) 49 12.9 (16.2) 15.0 (27.5) 2.9 (−9.0, 14.9) 0.31 ↓ 0.581b
Prostate complaints 39 34.4 (28.0) 36.1 (26.2) 49 37.6 (27.9) 40.7 (31.0) 1.8 (−4.9, 8.6) 0.04 ↓ 0.575
Chlamydia infections 49 9.9 (15.4) 8.9 (19.5) 39 7.8 (9.6) 6.3 (10.0) 2.2 (−9.5, 13.9) 0.74 ↑ 0.701
Thyroid dysfunction 49 178.9 (139.0) 206.1 (155.4) 39 160.6 (158.3) 186.1 (151.7) 3.9 (−26.3, 34.11) 0.03 ↓ 0.788
Perimenopausal
complaints
49 5.6 (6.2) 5.2 (6.0) 39 6.4 (7.6) 7.4 (8.5) −1.4 (−5.0, 2.1) 0.29 ↓ 0.404
The desired direction of change is given in the column headed ‘Direction’. Numbers represent the number of tests prescribed per 6 months per 1000 patients
n = number of practices
aAdjusted difference between groups at end of intervention, corrected for baseline
bStatistically significant interaction
Rheumatic complaints
P 10: B (95% CI):−7.8 (−22.0, 6.5). p: 0.257
P 90: B (95% CI): 16.3 (1.7, 30.9). p: 0.031
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GPs are more than ever controlled by external parties
such as the health inspectorate and healthcare insurers,
which may have led to a more defensive attitude among
GPs, resulting in higher test ordering rates.
Strengths and limitations of the research methods used
Lack of power: our efforts to implement the strategy
widely in the southern part of the Netherlands failed to
recruit a sufficient number of groups for the trial, leav-
ing us with an underpowered study. This could, in part,
have been caused by the pragmatic character of our trial,
with local pharmacists and experts on diagnostics
leading the recruitment effort and moderating the
groups. A major healthcare reform programme was
launched shortly after our recruitment started [38], caus-
ing frustration among many GPs due to the resulting
high administrative burden. This probably reduced their
willingness to participate in our trial.
Choice of outcome and lack of quality indicators: we
chose to express the volume of prescribed drugs in
DDDs. A risk of this is that not all DDDs are compatible
with the actual dosage physicians prescribe to a patient.
For diclofenac, for instance, the normal dosage is 1.5 to
2 DDDs every day. However, this did not affect the
Table 4 Intention-to-treat analysis of changes in prescribing rates showing sum scores per clinical topic and scores per drug
Intervention Control
Clinical topic n Mean before
(sd)
Mean after
(sd)
n Mean before
(sd)
Mean after
(sd)
Ba (95% CI) icc Direction p
Anaemia
Iron preparations, oral 39 25.0 (20.7) 45.1 (40.0) 49 27.4 (28.4) 49.2 (55.7) 3.9 (−13.9, 21.5) 0.21 = 0.644
Urinary tract infections
Antibiotics UTI 39 43.5 (31.6) 47.3 (36.5) 49 47.5 (38.7) 59.7 (48.7) 11.9 (−3.2, 27.0) 0.21 ↓ 0.113
Prostate complaints 39 59.1 (43.3) 107.1 (69.6) 49 66.5 (58.6) 127.5 (102.2) 20.0 (−20.9, 60.8) 0.38 ↓ 0.306
Alpha receptor blockers 39 49.6 (35.7) 86.6 (56.2) 49 55.0 (49.5) 103.3 (81.5) 18.5 (−15.3, 52.3) 0.42 ↓ 0.258
5 alpha reductase inhibitors 39 9.5 (9.5) 20.4 (18.6) 49 11.5 (11.2) 24.2 (24.7) 1.4 (−7.2, 10.0) 0.01 ↓ 0.735
Stomach complaints 49 329.7 (286.9) 612.0 (477.0) 39 282.6 (210.1) 491.8 (333.4) 106.7 (−70.7, 284.2) 0.63 ↓ 0.219
H2 antagonists 49 27.8 (26.4) 32.4 (30.0) 39 22.3 (20.5) 21.3 (16.4) 12.5 (−1.8, 26.8) 0.44 ↑ 0.081
Proton pump inhibitors 49 300.8 (262.9) 578.3 (452.3) 39 259.4 (192.3) 469.1 (322.1) 93.7 (−71.9, 259.4) 0.62 ↓ 0.246
Misoprostol 49 0.1 (0.4) 0.0 (0.2) 39 0.1 (0.4) 0.2 (0.5) −0.1 (−0.2,−0.0) 0.00 ↓ 0.008 b
Triple therapy (ATC A02BD04) 49 1.0 (1.7) 1.3 (2.0) 39 0.9 (1.3) 1.1 (1.7) 0.2 (−0.7, 1.2) 0.49 ↓ 0.593 b
Thyroid dysfunction 49 81.3 (66.3) 137.2 (102.6) 39 71.4 (48.9) 107.1 (71.6) 21.2 (−14.1, 56.6) 0.42 = 0.217
Thyroid hormones 49 74.8 (60.8) 125.0 (92.6) 39 66.9 (47.4) 100.8 (70.0) 18.2 (−16.0, 52.4) 0.45 = 0.269
Antithyroid preparations 49 6.5 (8.6) 12.2 (17.8) 39 4.5 (4.4) 6.3 (7.3) 2.6 (−1.7, 7.0) 0.09 ↑ 0.218 b
Perimenopausal complaints 49 56.4 (42.7) 56.8 (41.8) 39 46.3 (34.2) 46.0 (29.6) 6.6 (−12.0, 25.2) 0.56 ↓ 0.459
Oestrogens, oral 49 14.1 (13.6) 12.7 (12.1) 39 12.3 (11.8) 11.2 (10.4) 0.2 (−3.6, 4.1) 0.01 ↓ 0.889
Contraceptives (>50y) 49 3.6 (3.2) 6.4 (4.9) 39 3.2 (3.9) 5.9 (4.2) 1.1 (−1.9, 4.2) 0.34 ↓ 0.431
Hormone replacement
therapy
49 34.8 (28.6) 34.7 (27.0) 39 28.3 (19.7) 26.3 (17.8) 5.8 (−6.5, 18.0) 0.70 ↓ 0.331
Clonidine 49 0.5 (1.8) 0.5 (2.0) 39 0.2 (0.5) 0.4 (2.0) 0.1 (−1.0, 1.2) 0.13 ↓ 0.908 b
Tibolon 49 3.4 (4.1) 2.4 (2.7) 39 2.3 (2.8) 2.2 (3.4) −0.3 (−1.4, 0.8) 0.00 ↓ 0.615
The desired direction of change is given in the column headed ‘Direction’. Numbers represent the number of DDDs prescribed per 6 months per 1000 patients
n = number of practices
aAdjusted difference between groups at end of intervention, corrected for baseline
bstatistically significant interaction
Misoprostol
P 10: B (95% CI):−0.1 (−0.2,−0.0). p: 0.039
P 90: B (95% CI):−0.1 (−0.2,−0.0). p: 0.039
Triple therapy (ATC A02BD04)
P10: B (95% CI): 0.9 (−0.2, 1.9). p: 0.117
P90: B (95% CI):−0.4 (−1.6, 0.7). p: 0.413
Antithyroid preparations
P10: B (95% CI):−1.9 (−7.2, 3.4). p: 0.474
P90: B (95% CI): 12.3 (4.6, 19.9). p: 0.002
Clonidine
P10: B (95% CI): 0.6 (−0.4, 1.6). p: 0.215
P90: B (95% CI):−2.4 (−3.9,−1.0). p: < 0.001
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comparability of the two groups, as both were affected
by this form of distortion in the same way. If we had
been able to provide feedback on quality indicators as
well as volume data, a more valid insight into perform-
ance might have resulted, but with more interpretation
problems for the GPs. Also, using volume data only has
been proven to lower volumes especially in areas charac-
terised by overuse [22].
Change of the protocol after its publication: the fact
that all groups in the intervention arm, whether or not
they had chosen a specific topic, were analysed using the
intention-to-treat principle as if they had been exposed
to the topic may have diluted the effects of the interven-
tion. We would rather have analysed the effect of the
intervention on changes in the direction of shared work-
ing agreements, as stated in the protocol, but as these
were hardly established, we decided to use a per-
protocol analysis as the second best option, after the
protocol had been published.
Minimization of the Hawthorne effect: a strong
point of the design we used is that it minimized the
Hawthorne effect. On the downside, it might have
caused contamination of the effects if we had not ex-
posed all groups in the trial to the intervention at the
same time [30, 39, 40].
Comparison with other studies
Evaluating the effect of large-scale implementation of a
quality improvement strategy of proven effectiveness
using a pragmatic design like ours has not often been
performed. Earlier and ongoing work has focused mainly
on one particular clinical topic (e.g., prescribing antibiotics
for respiratory tract infections or X-rays for low back pain
patients), while we applied the peer review strategy to a
broad range of topics and focussed on both test ordering
and prescribing behaviour [41–45]. By researching whether
the results of more fully controlled trials were also found in
large-scale implementation, we sought to contribute to the
knowledge on ways to improve professional performance.
We are not aware of similar multi-faceted studies
using audit and feedback with peer group discussion in
this field that would allow direct comparison with our
study, although much is known about the individual
components we combined in our study.
Much work has been done on evaluating the effects of
audit and feedback on both test ordering and prescribing
behaviour in well-controlled trials. These interventions
show a modest but statistically significant positive effect
on changing professional behaviours but the heterogen-
eity of the trials prevents solid conclusions to be drawn
[35, 41, 46–52]. Although audit and feedback on test or-
dering behaviour embedded in peer review in small
groups has been found to be more effective than audit
and feedback alone, it generally remains unclear exactly
what factors contribute to this effect [10, 21, 53, 54].
The use of pragmatic designs in quality improvement re-
search contributes to bridging the gap between academia
and clinical practice [55, 56].
Multifaceted interventions like ours are complex by
nature but seem attractive because the individual effects
could add up. It remains unclear, however, whether
multifaceted interventions or single interventions are
more effective. Mostofian concluded in a review of re-
views that multifaceted interventions are most effective
Table 5 Per-protocol analysis of change in test ordering rates for each topic
Intervention control
Clinical topic n Mean before
(SD)
Mean after
(SD)
n Mean before
(SD)
Mean after
(SD)
Ba (95% CI) icc Direction p
Anaemia 35 176.8 (172.2) 209.4 (174.6) 53 199.6 (146.3) 232.5 (177.7) −9.1 (−96.1, 77.9) 0.60 ↓ 0.829
Rheumatic complaints 39 13.3 (22.9) 11.6 (20.7) 49 12.9 (16.2) 14.9 (27.5) 3.2 (−8.1, 14.6) 0.55 ↓ 0.551b
Prostate complaints 26 34.7 (24.6) 30.4 (29.3) 62 39.1 (27.4) 41.8 (29.5) 6.9 (−0.7, 14.6) 0.07 ↓ 0.072
Chlamydia infections 30 11.4 (21.5) 14.7 (23.3) 58 7.4 (8.8) 5.8 (9.5) −5.7 (−12.0, 0.5) 0.40 ↑ 0.069b
Thyroid dysfunction 29 204.8 (159.9) 191.3 (135.4) 59 163.3 (153.2) 191.7 (152.8) 36.6 (10.5, 62.7) 0.00 ↓ 0.007
Perimenopausal complaints 24 5.7 (5.5) 3.8 (3.5) 64 6.1 (6.7) 7.3 (8.0) 3.2 (0.1, 6.4) 0.10 ↓ 0.046b
The desired direction of change is given in the column headed ‘direction’. Numbers represent the number of tests prescribed per 6 months per 1000 patients
n = number of practices
aAdjusted difference between groups at end of intervention, corrected for baseline
bStatistically significant interaction
Rheumatic complaints
P10: B (95% CI):−3.0 (−13.9, 8.0). p: 0.560
P90: B (95% CI): 14.8 (2.1, 27.4). p: 0.025
Chlamydia infections
P10: B (95% CI):−2.3 (−9.0, 4.4) p: 0.482
P90: B (95% CI):−10.4 (−17.6,−3.3) p: 0.006
Perimenopausal complaints
P10: B (95% CI): 0.7 (−3.0, 4.5). p: 0.696
P90: B (95% CI): 6.6 (2.4, 10.7). p: 0.002
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in changing professional behaviour [57]. On the other
hand, Irwin et al. concluded that there is no evidence for
a larger effect of combined interventions, while Johnson
and May find it likely that multifaceted interventions are
more effective [52, 54].
Studies embedding the discussion of clinical topics in
LQICs have reported a modest positive effect on prescrib-
ing costs and quality [14, 58–62]. Our finding, based on
the per-protocol analysis, that groups with the highest vol-
umes at baseline showed the largest improvement, is in
line with the results presented by Irwin et al. [52].
Implications for future research
The problems on the fidelity of the feedback and with
the uptake of the intervention could best be handled by
assuring that a strong leader picks up the group and lead
them forward. It may also be helpful to identify GPs with
a low quality baseline performance representing an un-
warranted deviation from the mean and target those
GPs in this type of quality improvement initiatives.
Other physicians who are already doing well can con-
centrate on what they are doing already; delivering high
quality care. Further research is needed on whether low
baseline performance is consistent behaviour for an indi-
vidual GP. Also further research on the cut-off point for
participants that can benefit from a quality improvement
intervention like this is needed to clarify the population
to be targeted best. Potential downsides of such an
approach such as the loss of peer learning with learning
from the best practices need to be addressed as well.
Table 6 Per-protocol analysis of change in prescribing rates, showing sum scores per clinical topic and drug
Intervention Control
Clinical topic N Mean before
(sd)
Mean after
(sd)
n Mean before
(sd)
Mean after
(sd)
Ba (95% CI) icc Direction p
Anaemia
Iron preparations. oral 35 29.5 (22.5) 38.7 (25.6) 53 26.6 (27.6) 46.9 (54.2) 18.9 (−3.9, 41.7) 0.43 = 0.098
Urinary tract infections
Antibiotics UTI 8 40.8 (24.0) 44.5 (29.7) 80 46.5 (36.3) 55.3 (44.8) 6.3 (−21.1, 33.8) 0.33 ↓ 0.623
Prostate complaints 26 68.5 (47.0) 79.5 (63.0) 62 65.5 (53.6) 125.9 (91.9) 28.5 (6.5, 50.7) 0.27 ↓ 0.016
Alpha receptor blockers 26 57.5 (41.1) 66.5 (54.2) 62 54.0 (44.9) 101.5 (73.2) 44.2 (6.0, 82.3) 0.49 ↓ 0.027
5 alpha reductase inhibitors 26 11.0 (7.5) 13.0 (11.7) 62 11.5 (11.0) 24.5 (22.9) 11.1 (2.1, 20.2) 0.05 ↓ 0.020
Stomach complaints 28 455.1 (294.7) 565.2 (303.7) 60 275.7 (253.8) 509.1 (433.0) 61.1 (15.0, 107.2) 0.11 ↓ 0.014 b
H2 antagonists 28 28.0 (22.4) 32.4 (26.8) 60 23.2 (22.35) 24.2 (22.6) −2.4 (−21.5, 16.7) 0.68 ↑ 0.788
Proton pump inhibitors 28 425.9 (276.1) 531.5 (283.8) 60 251.6 (234.0) 483.7 (414.7) 254.8 (60.1, 449.5) 0.66 ↓ 0.014 b
Misoprostol 28 0 (0) 0 (0) 60 0.1 (0.4) 0.1 (0.45) 0.1 (−0.1, 0.2) 0.01 ↓ 0.365
Triple therapy (ATC A02BD04) 28 1.2 (2.5) 1.4 (1.8) 60 0.9 (1.2) 1.1 (1.6) 0.1 (−0.7, 0.8) 0.20 ↓ 0.878b
Thyroid dysfunction 29 82.2 (45.9) 99.2 (57.5) 59 86.0 (63.1) 128.5 (94.6) 12.6 (0.7, 24.4) 0.08 = 0.040
Thyroid hormones 29 76.7 (43.5) 91.1 (52.2) 59 79.5 (58.8) 118.3 (87.8) 25.2 (2.1, 48.3) 0.19 = 0.035
Antithyroid preparations 29 5.5 (7.4) 8.2 (13.2) 59 6.5 (7.7) 10.1 (14.0) 0.2 (−4.2, 4.6) 0.11 ↑ 0.927
Perimenopausal complaints 24 59.4 (31.9) 56.5 (25.9) 64 51.2 (40.0) 51.3 (40.0) 1.5 (−2.3, 5.4) 0.21 ↓ 0.414
Oestrogens. oral 24 11.5 (8.0) 9.7 (6.2) 64 14.0 (14.0) 12.3 (12.4) 1.0 (−3.6, 5.5) 0.03 ↓ 0.612
Contraceptives (>50y) 24 5.1 (2.8) 5.9 (2.7) 64 3.2 (3.6) 6.5 (5.1) 2.5 (−0.9, 5.8) 0.31 ↓ 0.137
Hormone replacement therapy 24 38.7 (24.2) 36.3 (21.0) 64 31.1 (24.4) 29.8 (24.4) 2.6 (−9.7, 14.9) 0.60 ↓ 0.652
Clonidine 24 0.6 (1.5) 0.7 (2.7) 64 0.4 (1.5) 0.4 (1.6) −0.3 (−1.4, 0.7) 0.11 ↓ 0.508 b
Tibolon 24 3.6 (3.7) 3.8 (4.1) 64 2.6 (3.0) 2.3 (3.3) −0.7 (−2.0, 0.6) 0.00 ↓ 0.294 b
The desired direction of change is given in the column headed ‘Direction’. Numbers represent the number of DDDs prescribed per 6 months per 1000 patients
n = number of practices
aAdjusted difference between groups at end of intervention, corrected for baseline
bStatistically significant interaction
Thyroid dysfunctioning: Clonidine
P10: B (95% CI): 30.3 (15.1, 45.5). p: <0.001 P10: B (95% CI): 0.4 (−0.4, 1.2). p: 0.327
P90: B (95% CI): 186.7 (88.7, 284.7). p: <0.001 P90: B (95% CI):−1.3 (−2.2,−0.4). p: 0.005
Stomach complaints: Tibolon
P10: B (95% CI): 1.4 (−39.6, 42.6). p: 0.937 P10: B (95% CI): 0.9 (−0.8, 2.6). p: 0.297
P90: B (95% CI): 408.8 (341.1, 476.5). p: <0.001 P90: B (95% CI):−2.3 (−4.0,−0.6). p: 0.008
PPIs: Triple therapy (ATC A02BD04)
P10: B (95% CI): 91.5 (−120.0, 303.0). p: 0.378 P10: B (95% CI):−0.8 (−1.9, 0.3). p: 0.133
P90: B (95% CI): 347.4 (159.2, 0.8). p: <0.001 P90: B (95% CI): 1.4 (0.3, 2.5). p: 0.014
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Further pragmatic research should be performed to con-
firm our findings that the results found in earlier well-
controlled trials are not easily replicated. We therefore
encourage other researchers to perform vigorous large
scale evaluations of complex implementation strategies,
preferably embedded and owned by the field, as we did
Conclusions
Our intervention, which aimed at changing the test order-
ing and prescribing behaviour of GPs by means of auditing
and feedback, embedded in LQICs, with academia at a dis-
tance, shows that the favourable results of earlier work
could not be replicated. It appeared that large-scale uptake
of evidence-based but complex implementation strategies
with a minimum of influence of external researchers, but
with the stakeholders in healthcare themselves being
responsible for the work that comes with integrating
this intervention into their own groups, was not feas-
ible. Although our study suffered from a lack of power,
we expect that even if a sufficient number of groups
had been included, no clinically relevant changes would
have been observed.
Additional files
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